Rho-kinase plays an important role in hypertension and is reported to interfere with insulin signaling through serine phosphorylation of insulin receptor substrate-1 (IRS-1) in cultured vascular smooth muscle cells. We therefore examined the role of Rho-kinase in the development of insulin resistance in Zucker obese rats. In skeletal muscles and aortic tissues of Zucker obese rats, activation of RhoA/Rho-kinase was observed. Long-term Rho-kinase inhibition by 4 wk treatment with fasudil (a Rho-kinase inhibitor) not only reduced blood pressure but corrected glucose and lipid metabolism, with improvement in serine phosphorylation of IRS-1 and insulin signaling in skeletal muscles. Direct visualization of skeletal muscle arterioles with an intravital CCD videomicroscope demonstrated that both acetylcholine-and sodium nitroprusside-induced vasodilations were blunted, which were restored by the fasudil treatment. Furthermore, both fasudil and Y-27632 prevented the serine phosphorylation of IRS-1 induced by insulin and/or tumor necrosis factor-α in skeletal muscle cells. Collectively, Rho-kinase is responsible for the impairment of insulin signaling and may constitute a critical mediator linking between metabolic and hemodynamic abnormalities in insulin resistance.
of insulin to activate insulin receptor (IR)/insulin receptor substrate (IRS)-1/phosphatidylinositol 3-kinase (PI3K)/Akt pathway (6, 7) . This pathway is involved in both insulin-induced glucose uptake in skeletal muscles (8) and insulin-induced production of nitric oxide (NO) in endothelial cells (9) . Of the insulin-signaling pathway, IRS proteins are important signaling molecules mediating insulin action in target cells. Recently, serine phosphorylation of IRS proteins has been implicated as a mechanism mediating the attenuated insulin signaling and is responsible partly for insulin resistance (10) . Although various cytokines or metabolites, including tumor necrosis factor (TNF)-α, free fatty acid (FFA), and insulin, obviously promote serine phosphorylation of IRS-1 and cause insulin resistance (10) , the precise mechanism for serine phosphorylation of IRS-1 or the link between these malign factors and the development of hypertension has not been elucidated fully.
Rho-kinase, an effector of the small G protein RhoA, contributes importantly to various biological functions (11) . It has been documented that Rho-kinase inhibitors reduce blood pressure in hypertensive animals, and Rho-kinase participates in the regulation of systemic vascular tone (12, 13) and endothelial function (14, 15) . Recently, Rho-kinase has been reported to interfere with insulin signaling in vitro. In vascular smooth muscle cells (VSMC), activation of Rho-kinase pathway increases the association between Rho-kinase and IRS-1, resulting in serine phosphorylation of IRS-1 and the subsequent inhibition of insulin signaling (16) . Although these in vitro data indicate the interaction between Rho-kinase and insulin signaling, the role of Rho-kinase in mediating the insulin resistance in obesity has not been examined.
In this study, we investigated whether the activation of the RhoA/Rho-kinase pathway in the skeletal muscle and the aorta participated in the development of insulin resistance and hypertension in the insulin-resistant animal. To test these issues, we evaluated the effect of longterm inhibition of Rho-kinase on the progression of insulin resistance and hypertension in Zucker obese rats. Furthermore, we attempted to clarify the mechanisms underlying insulin-induced and/or TNF-α-induced insulin resistance in the skeletal muscle, which might endorse the in vivo observations.
MATERIALS AND METHODS

Animals
This study was performed in accordance with the institutional guideline of the Animal Care and Experimentation Committee. Ten-week-old male Zucker lean (fa/-, n=27) and obese rats (fa/fa, n=57; Charles River, Kanagawa, Japan) were fed a standard diet (Nippon Clea, Tokyo, Japan). In this study, we tested the effect of fasudil (Asahi Kasei, Tokyo, Japan) as a Rho-kinase inhibitor, because it is the only Rho-kinase inhibitor practically available for long-term in vivo use. This agent acquires unique characteristics when administered in vivo; its metabolite, hydroxyfasudil, still retains its activity and possesses a more selective action than its parent drug on Rho-kinase (specificity for Rho-kinase is 100 times higher for PKC and 1000 times higher for myosin light chain kinase; refs 13, 14, 17) . Zucker obese rats received either vehicle (n=20), 3 mg/kg/day fasudil (n=11), 10 mg/kg/day fasudil (n=6), or 20 mg/kg/day fasudil (n=20) by intraperitoneal injection for 4-5 wk. Zucker lean rats received either vehicle (n=19) or 20 mg/kg/day fasudil (n=8). Systolic blood pressure was measured by the tail-cuff method (Softron BP-98A; Softron, Tokyo, Japan). Oral glucose tolerance test (OGTT) and insulin tolerance test (ITT) were performed after 4-5 wk treatment with fasudil. Rectal temperature was measured using an electron thermistor equipped with a rectal probe (Model TD-300; Shibaura Electronics, Saitama, Japan).
Skeletal muscle tissues and aorta preparation and immunoblot analysis
In vivo insulin stimulation was performed after 5 wk of treatment with fasudil (18). After tissues were lysed in solubilization buffer, immunoblot analysis was performed as described previously (19) , with some modifications. Blots were incubated with specific antibodies against IRS-1, phospho-IRS-1(Ser 307 ), Akt, phospho-Akt(Thr 308 ; Upstate Biotechnology, Lake Placid, NY), Rho-kinase-α (BD Biosciences PharMingen, San Diego, CA), and myosin phosphatase target subunit (MYPT; Santa Cruz Biotechnology, Santa Cruz, CA). Rho-kinase activity was determined by the phosphorylated MYPT level with an antibody that specifically recognized MYPT phosphorylation at Thr 696 (Upstate) (20) .
Immunoprecipitations were performed as detailed previously (19) , with antibodies against IRS-1 and phospho-tyrosine (4G10) (Upstate). The protein of both membrane and cytosolic compartments was fractionated (21) and subjected to SDS-PAGE and immunoblotting with antibodies against RhoA (Santa Cruz Biotechnology), glucose transporter type 4 (GLUT4) (Chemicon International, Tamacula, CA), and caveolin-1 (BD Biosciences PharMingen). Band intensities were quantified and normalized by the those of appropriate proteins with the Scion Image software (Scion Corp, Fredrick, MD), and the results were presented as fold induction of the protein expression in skeletal muscles and aorta from lean rats.
Cell culture
A myoblast cell line, C2C12 cell (RIKEN Cell Bank, Ibaraki, Japan), was cultured and induced to differentiate into a myotube (22) . After serum starvation, the cells were pretreated with Rhokinase inhibitors, Y-27632 (10 μmol/l, Calbiochem, San Diego, CA), or fasudil (10 μmol/l) for 30 min before the stimulation with insulin (100 nmol/l, Sigma-Aldrich, St. Louis, MO) and/or TNF-α (10 ng/ml, Sigma). After appropriate-period stimulation (see figure legends), cells were harvested and subjected to immunoblot analysis as described previously (19) . The primary antibodies against the following molecules were used: phospho-MYPT, MYPT, IRS-1, and phospho-IRS-1(Ser 307 ).
Direct visualization of skeletal muscle artery by CCD camera
Ten-week-old male Zucker lean (n=5) and obese rats (n=10) were used for the experiment. Five obese rats were treated with 3 mg/kg/day fasudil for 4 wk. The model of the videomicroscopy used had been detailed elsewhere (23, 24) . The visualization of the gastrocnemius muscle arteriole in a prone position hampers rats from breathing, whereas insulin signaling cascade, glucose uptake, and endothelial function are reportedly impaired in quadriceps in insulin resistance state (25, 26) . We therefore adopted the quadriceps muscle for evaluating the microvascular responsiveness to intravenous administration of acetylcholine (ACh; Sigma) and sodium nitroprusside (SNP; Maruishi Seiyaku, Tokyo, Japan). Under the pentobarbital anesthesia, the pencil lens-probe CCD videomicroscope was introduced into the skeletal muscle at a depth of several millimeters. The doses of ACh or SNP used (i.e., 0.1-3 µg/kg/min) were determined because at these doses blood pressure was unaltered. Each dose of ACh or SNP was infused for 8 min, and the infusion of each drug was interposed by 15-min saline infusion, during which time arteriolar diameter returned to basal levels. Images on the CCD were converted into black and white video signals every 33 msec and recorded on a video cassette tape. Vessel diameters were measured before and after the infusion of ACh, SNP, or saline (23, 24, 27) .
RNA extraction and real-time PCR
Total RNA was extracted from the rat epididymal and brown adipose tissue (BAT) using RNeasy lipid tissue kit (Qiagen, Valencia, CA). Total RNA was subjected to reverse transcription in a 20 μl reaction containing random primers and Superscript II enzyme (Invitrogen, Carlsbad, CA). Quantitative real-time PCR was performed with an ABI Prism 7700 Sequence Detection System using SYBR ® Green PCR Master Mix Reagent Kit (Applied Biosystems, Foster City, CA). Primers used were as follows: TNF-α, sense: 5′-GGTGATCGGTCCCAACAAGGA-3′, antisense: 5′-CACGCTGGCTCAGCCACTC-3′; uncoupling protein-1 (UCP-1), sense: 5′-ATCTTCTCAGCCGGCGTTT-3′, antisense: 5′-TGGATCTGAAGGCGGACTTT-3′. PCRamplified products were also electrophoresed on agarose gels to confirm that single bands were amplified. Levels of mRNA were normalized to those of GAPDH (primers commercially available from Applied Biosystems).
Statistical analysis
Data are mean ± SE. Data were analyzed by one-way or two-way ANOVA as appropriate, followed by Bonferroni's post hoc test. P < 0.05 was considered statistically significant.
RESULTS
Systolic blood pressure and Rho-kinase activity in the aorta
In Zucker obese rats, treatment with 3 mg/kg/day fasudil did not affect blood pressure throughout the experimental period (2 wk, 113±3 vs. 111±2 mmHg; 4 wk, 122±3 vs. 120±2 mmHg, for control and fasudil-treated Zucker obese rats, respectively, n=6), whereas higher doses of fasudil reduced blood pressure in a dose-dependent manner; 20 mg/kg/day fasudil lowered blood pressure to the same level of lean rats (Fig. 1A) . In lean rats, administration of 20 mg/kg/day fasudil did not affect blood pressure.
To examine whether the inhibition of Rho-kinase exerted direct blood pressure lowering effect, a single administration of fasudil was performed in both rat strains at 10 wk of age (n=4; Fig. 1B ). In obese rats, the blood pressure lowering effect of fasudil was significantly exaggerated compared with lean rats.
Translocation of RhoA from the cytosolic to the membrane fraction was determined as a parameter of its stimulation (28). In the aorta of obese rats, the level of RhoA in the membrane fraction was elevated (Fig. 1Ca) . Next, the activity of Rho-kinase was evaluated with the use of phospho-MYPT levels (20) . The activity of Rho-kinase was markedly increased in the aorta from obese rats, which was suppressed by the treatment with fasudil in a dose-dependent manner (Fig.  1Cd ).
Body weight, blood glucose, insulin, and lipid levels
In lean rats, fasudil had no effect on the changes in body weight or metabolic parameters (Fig. 2) . In obese rats, 4 wk treatment with 3 mg/kg/day fasudil did not alter the changes in body weight, whereas there were fewer increases in body weight in rats treated with higher doses of fasudil ( Fig. 2A) . Fasting blood glucose levels did not differ among lean and obese rats (Fig. 2B) . Plasma insulin concentrations were higher in obese rats than in lean rats and were partially restored by the treatment with fasudil in a dose-dependent manner (Fig. 2C) . In obese rats, 5 wk treatment with fasudil reversed the increased levels of triglyceride and FFA in a dose-dependent manner, although cholesterol levels were unaffected (Fig. 2D-F) .
Effect of a higher dose of fasudil on body weight and adiposity
The treatment with 20 mg/kg/day fasudil markedly mitigated the increase of body weight in Zucker obese rats. Thus, the body weight in fasudil-treated obese rats was significantly less than in obese rats at 2 wk, and this effect persisted throughout the study (Fig. 3A) .
To elucidate the mechanism for the diminished body weight gain in the fasudil-treated rats, we evaluated food intake and energy expenditure. Food intake was not different between the fasudiltreated rats and control obese rats (Fig. 3B) . As previously reported (29), rectal temperature was lower in Zucker obese rats than in lean rats. Surprisingly, treatment with fasudil significantly elevated the rectal temperature in obese rats (Fig. 3C) . The weight of interscapular BAT was markedly greater in obese rats than in lean rats and was significantly reduced by fasudil only in obese rats (Fig. 3D) . Concomitantly, the UCP-1 expression in BAT was suppressed in obese rats, and fasudil restored this expression in obese rats (Fig. 3E) .
We further examined the effects of fasudil on adiposity. Fasudil ameliorated fat accumulation in epididymal and mesenteric tissues of obese rats ( Fig. 3F and G) but had no effect on liver weight (Fig. 3H ). In parallel with these changes in adiposity, increased levels of TNF-α in epididymal fat pads were restored by the treatment with fasudil (Fig. 3I) .
Glucose tolerance and insulin sensitivity
The amelioration of hyperinsulinemia in fasudil-treated obese rats suggested improvement of insulin sensitivity and glucose metabolism. We therefore examined OGTT and ITT in rats in each group. In lean rats, the treatment with fasudil did not affect the changes in blood glucose levels induced by OGTT (Fig. 4A) . In contrast, in obese rats, fasudil improved the glucose tolerance in a dose-dependent manner. At 3 mg/kg/day, fasudil reduced the area under the curve by 47%, compared with the obese rats. Intraperitoneal injection of insulin had little effect on blood glucose concentrations in untreated obese rats (Fig. 4B) . The same dose of insulin, however, elicited dose-dependent decreases in plasma glucose levels in fasudil-treated rats. In lean rats, the insulin injection elicited marked decreases in plasma glucose concentrations to the level below ~20%.
Effect of fasudil on Rho-kinase pathway and insulin signaling in skeletal muscles
To explore the signal transduction mechanism by which the inhibition of Rho-kinase ameliorated insulin sensitivity in obese rats, we conducted a series of experiments examining the molecular changes in skeletal muscle tissues. To rule out the possibility that the effects of fasudil on body weight and/or blood pressure contributed to the improvement in insulin sensitivity, muscle tissues were obtained from obese rats treated with 3 mg/kg/day fasudil, a dose that did not affect the changes in body weight or blood pressure. In the skeletal muscle of obese rats, the level of RhoA in the membrane fraction was elevated (Fig. 5Aa) . Although there was no difference in the protein expression of Rho-kinase, phosphorylation of MYPT was significantly increased in obese rats, compared with lean rats (Fig. 5Ac) . The increased phospho-MYPT in obese rats was substantially suppressed by the treatment with fasudil.
Activated Rho-kinase can reportedly antagonize insulin signaling through serine phosphorylation of IRS-1 (16) . Immunoblotting using a phospho-specific antibody against Ser 307 of IRS-1, a major phosphorylation site of IRS-1 responsible for inhibitory effects on insulin signaling (30) , showed increased serine phosphorylation of IRS-1 in obese rats, which was inhibited by fasudil (Fig. 5Ad) . We further examined whether the inhibition of Rho-kinase restored the insulin signaling. In obese rats, pronounced decreases in insulin-stimulated tyrosine-phosphorylation of IRS-1, phosphorylation status of Akt, and translocation of GLUT4 to the cell membrane were observed (Fig. 5B) . These changes were rescued in rats treated with fasudil.
Insulin and TNF-α modulate Rho-kinase pathway
As already shown in other cells (31, 32) , insulin and/or TNF-α activated Rho-kinase in skeletal muscle cells, C2C12 cells (Fig. 6A) . Two Rho-kinase inhibitors abolished the serine phosphorylation of IRS-1 induced by TNF-α and insulin ( Fig. 6B and C) . These data indicate that the Rho-kinase inhibitor exerts insulin-sensitizing effects at least in part through its direct effects on the skeletal muscle cells.
Vascular responsiveness to ACh and SNP in skeletal muscle microvasculature
We examined the effects of fasudil on the vasodilatory response of skeletal muscle arterioles to ACh and SNP by using a pencil lens-probe videomicroscope. To eliminate any confounding effect of the changes in blood pressure on arteriolar responses, the 3 mg/kg/day fasudil-treated group was used for microvascular observation. Insertion of the CCD probe into the skeletal muscle offers clear visualization of skeletal microcirculation (Fig. 7A-C) . There was no difference in baseline diameters observed among three groups (lean rats, 11.1±1.2 μm; control obese rats, 11.9±0.5 μm; obese+fasudil 3 mg/kg/day, 12.8±0.8 μm, respectively, n=5). In lean rats, ACh markedly increased arteriolar diameter, but this response was blunted in obese rats ( Fig. 7A and B) . Chronic treatment with a subdepressor dose (3 mg/kg/day) of fasudil significantly restored the ACh-induced vasodilation, with 24.5 ± 4.3% relaxation (vs. 10.1±1.5% relaxation in obese rats, P<0.05) observed in response to 3 µg/kg/min ACh (Fig. 7A-D) . In lean rats, SNP also increased arteriolar diameter in a dose-dependent manner (Fig. 7E) . In obese rats, however, the vasodilator response was blunted. Four-week treatment with fasudil (3 mg/kg/day) significantly restored the vasodilator response to SNP in skeletal muscle arterioles of obese rats; at 3 µg/kg/min, SNP elicited 20.3 ± 0.8% vasodilation, a response greater than that in obese rats (14.3±2.7% vasodilation, P<0.05, n=5).
DISCUSSION
In the present study, we have demonstrated that the RhoA/Rho-kinase pathway is activated in Page 6 of 20 (page number not for citation purposes) vascular tissues of obese rats, which contributes to the development of hypertension. Furthermore, activated Rho-kinase disturbed the insulin signaling in the skeletal muscle and the vascular responsiveness to both ACh and SNP, thereby aggravating whole-body insulin sensitivity. Indeed, chronic Rho-kinase inhibition ameliorates metabolic disturbances and lowers blood pressure in rats manifesting insulin resistance. Since the skeletal muscle is the principal site of the insulin-mediated glucose uptake (2), the strategy to improve insulin sensitivity in skeletal muscles by Rho-kinase inhibition is expected to offer a promising approach to the prevention, intervention, and treatment of these pathological conditions.
Role of Rho-kinase in obesity and hypertension
Insulin resistance causes hypertension through multiple mechanisms, including the deranged NO system (33), hyperreactivity of VSMC (34) , and impaired pressure-natriuresis (35) . The Rhokinase pathway plays an important role in modulating VSMC tone and thereby is involved in the increased systemic vascular resistance in hypertension (12) . Our present study demonstrates that Rho-kinase is activated in the aorta of obese rats, and the administration of fasudil preferentially lowers blood pressure in obese but not lean rats (Fig. 1) , indicating a selective increase in vascular tone by the activated Rho-kinase in obese rats. It is reasonable therefore to conjecture that Rho-kinase constitutes an important determinant of the development of hypertension as a central molecule linking these impaired vasoregulatory systems and insulin resistance.
Role of Rho-kinase in metabolic disturbances
The present study demonstrates that fasudil increases glucose clearance and improves insulin sensitivity (Fig. 4) . Improved insulin sensitivity and metabolic milieu by the Rho-kinase inhibition are also reflected by the amelioration of hyperinsulinemia and elevated triglyceride/FFA levels (Fig. 2) . Of note, 3 mg/kg/day fasudil ameliorated glucose homeostasis without alterations in body weight or blood pressure. Furthermore, insulin sensitivity (assessed by ITT) was enhanced as early as 1 wk after the initiation of fasudil (20 mg/kg/day) treatment when changes in body weight were not apparent (data not shown). Taken together, we conclude that fasudil exerts direct insulin-sensitizing actions, rather than indirect effects after the changes in body weight.
Insulin resistance is a common pathological state in which target cells fail to respond to ordinary levels of circulating insulin. Recent studies have focused on serine phosphorylation of IRS-1 as a key negative feedback in response to insulin and TNF-α (10). Furthermore, using fibroblasts derived from mice lacking the Rho-inhibitory protein, p190-B RhoGAP, Sordella et al. (36) have shown that serine phosphorylation of IRS-1 is increased in these cells and that insulin signaling can be rescued by Y-27632. It is anticipated therefore that TNF-α and hyperinsulinemia may play important roles as possible activators for Rho-kinase and subsequently participate in the impaired insulin signaling in muscle tissues from obese rats (Fig. 6A) . Indeed, both TNF-α contents in the adipose tissue (Fig. 3I ) and plasma insulin (Fig. 2C) are elevated in Zucker obese rats, and the blockade of TNF-α activity is reported to ameliorate insulin resistance (37) . Although improvement in plasma insulin/FFA (Fig. 2) and reduction of TNF-α production (Fig.  3I) can also contribute to attenuation of serine phosphorylation of IRS-1 (10), the present study clearly indicates that pharmacological inhibition of Rho-kinase attenuates serine phosphorylation of IRS-1 and augments insulin signaling, with parallel restoration of GLUT4 translocation and amelioration of insulin sensitivity in obese rats (Figs. 4-6) . Collectively, it appears that Rho-kinase constitutes a potential candidate for negative regulators of IRS-1 function by serine phosphorylation.
Of note, we observe that higher doses of fasudil (10 and 20 mg/kg/day) reduce body weight ( Figs. 2A and 3A ) and fat masses (Fig. 3 ) in obese rats, but these effects are not seen in lean rats, which rather precludes the idea that body weight reduction is attributed to drug toxicity. Alternatively, the decrease in body weight is principally attributed to increased energy expenditure (Fig. 3C) . In this regard, in rodents the BAT plays a central role in maintaining energy balance and thermogenesis (38, 39) . Furthermore, UCP-1 constitutes a major positive regulator of thermogenesis in the BAT (40) . Indeed, as shown in the present study (Fig. 3E) , UCP-1 levels in the BAT are relatively low in obese rodents (41, 42) . More importantly, fasudil markedly restored the UCP-1 level in obese rats. These observations therefore lend support to the formulation that the activated Rho-kinase impairs thermogenesis and energy expenditure in the BAT of Zucker obese rats through the down-regulation of UCP-1, and the pharmacological intervention of Rho-kinase would up-regulate UCP-1 mRNA and subsequently correct thermogenesis and obesity. Of note, insulin has been shown to up-regulate UCP-1 expression through the IRS-1/PI3K/Akt pathway in brown adipocytes (43) . The improved insulin signaling by Rho-kinase inhibition, therefore, is expected to increase UCP-1 expression and therefore affect adiposity. This speculation requires further investigations.
Role of Rho-kinase in skeletal muscle arterioles
Endothelium-derived NO participates in the vasodilator action of insulin, and stimulation of NO production through IR/IRS-1/PI3K/Akt/eNOS has been demonstrated in human endothelial cells (9) . In the skeletal muscle vascular bed of obese patients in which insulin resistance has developed, both endothelium-dependent vasodilation and insulin-mediated augmentation of endothelium-dependent vasodilation are impaired (44) . It has also been demonstrated that NOmediated vasodilation is impaired in obese diabetic patients (45) . A growing body of evidence has been accumulated that Rho-kinase participates in the regulation of the contractile activity serving as a Ca 2+ sensitizer in the VSMC (12) . In VSMCs of resistance arteries, NO exerts its dilatory action mainly by reducing Ca 2+ sensitivity, and the inhibition of RhoA/Rho-kinase augments NO-induced dilation (46) . The present study demonstrates that the SNP-induced vasodilation of skeletal muscle arterioles is impaired in obese rats (Fig. 7E) . Furthermore, the Rho-kinase inhibition by fasudil ameliorates the blunted response to SNP. These observations therefore indicate that the endothelium-independent vasodilation is impaired in Zucker obese rats and further extend the possibility that Rho-kinase activation is responsible for the altered responsiveness in the VSMC. In this regard, Ca 2+ sensitivity is increased in VSMC from insulinresistant Goto-Kakizaki rats because of the activation of Rho-kinase (34) . Although we demonstrate that the effect of fasudil on ACh-induced vasodilation is explained by the improved sensitivity of VSMC to NO, the possibility still remains that fasudil acts on endothelial cells to ameliorate its function (14, 15) . Indeed, we have recently found in a preliminary study that TNF-α causes activation of Rho-kinase and down-regulation of eNOS in human umbilical endothelial cells, and these changes are restored by the Rho-kinase inhibition with fasudil or Y-27632 (unpublished observations). Alternatively, improvement of vascular function and insulin sensitivity by the treatment with fasudil could also be attributed to an attenuation of TNF-α production per se ( Fig. 3I; ref 47) . Collectively, inhibition of Rho-kinase would teleologically correct the insulin resistance-related vascular dysfunction and may also contribute partly to the amelioration of insulin sensitivity.
In conclusion, we have demonstrated that the activity of the RhoA/Rho-kinase pathway is increased in the skeletal muscle and the vasculature of insulin-resistant Zucker obese rats. Furthermore, long-term inhibition of Rho-kinase prevents the development of various aspects of metabolic syndrome, including hypertension, insulin resistance, dyslipidemia, and obesity. These beneficial actions are attributed mainly to the restoration of insulin signaling and/or to the vasorelaxant action on the arteriole feeding skeletal muscles. Thus, Rho-kinase constitutes a critical determinant acting as a key mediator for cross-talk between metabolic and hemodynamic abnormalities in insulin resistance. The results obtained from the current investigation may therefore have important implications that the inhibition of Rho-kinase serves to reduce the risks of cardiovascular disease associated with insulin resistance and would provide the therapeutic strategy for the treatment of metabolic syndrome. 1 . Long-and short-term effects of fasudil on blood pressure. A) 4 wk treatment with 3 mg/kg/day fasudil did not affect blood pressure, whereas higher doses reduced blood pressure. Each bar is mean ± SE (n=4−6). *P < 0.05 vs. lean; **P < 0.01 vs. lean; † P < 0.05 vs. obese; † † P < 0.01 vs. obese; ∫∫ P < 0.01 vs. obese fasudil 3 mg/kg/day; ## P < 0.01 vs. obese + fasudil 10 mg/kg/day. B) Single administration of 10 and 20 mg/kg fasudil preferentially reduced blood pressure in obese (filled symbols) but not lean rats (open symbols). In both lean and obese rats, fasudil at a dose of 3 mg/kg did not change blood pressure (open and filled squares). Values are mean ± SE (n=4). ∫∫ P < 0.01 vs. 0 h; ## P < 0.01 vs. obese + fasudil 10 mg/kg. C) Translocation of RhoA into membrane fraction was increased in aorta of Zucker obese rats (a). Levels of RhoA in cytosol fraction and Rho-kinase expression were not different between lean and obese rats (b, c). Phosphorylation of MYPT in vasculature was increased in obese rats, which was attenuated by treatment with fasudil in a dose-dependent manner (d). Densitometric analysis of immunoblots is shown as fold-induction of protein expression in the aorta from lean rats after normalized with expression level of total RhoA (a) and MYPT (d) in same tissue lysates. **P < 0.01 vs. lean; † † P < 0.01 vs. obese; ∫∫ P < 0.01 vs. obese + fasudil 3 mg/kg/day; # P < 0.05 vs. obese + fasudil 10 mg/kg/day. triglyceride (D), free fatty acid (FFA; E), and total cholesterol (TC; F) were increased in Zucker obese rats (solid bars), compared with lean rats (open bars). In obese rats, treatment with fasudil decreased insulin, triglyceride, and FFA levels but did not alter TC level. Each bar is mean ± SE (n=4−6). **P < 0.01 vs. lean; † P < 0.05 vs. obese; † † P < 0.01 vs. obese; ∫ P < 0.05 vs. obese + fasudil 3 mg/kg/day; ∫∫ P < 0.01 vs. obese + fasudil 3 mg/kg/day; # P < 0.05 vs. obese + fasudil 10 mg/kg/day; ## P < 0.01 vs. obese + fasudil 10 mg/kg/day. Representative images of microvasculature in skeletal muscle were shown (A−C). ACh (3 µg/kg/min) elicited increases in arteriolar diameter in lean rats (A). In obese rats, ACh-induced relaxation was impaired (B), and this impairment was improved by long-term treatment with fasudil (C). Percent changes in arteriolar diameter above baseline in response to graded infusion of ACh (D) and SNP (E) were shown. Values are mean ± SE (n=5). *P < 0.05 vs. lean; **P < 0.01 vs. lean; † P < 0.05 vs. obese.
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